FDA hopes to lay the groundwork to expand the role of digital health technologies in drug development and reviews and increase reliance on decentralized trials as part of the seventh iteration of the prescription drug user fee agreements. House lawmakers have expressed support for the agency’s plans, while also touting legislation they think could help boost the efforts. Digital health technologies can help with conducting decentralized trials in which some or all trial-related procedures and data collection take place at...